18 min listen
Biogen’s High Hopes For Gene Therapy, Ophthalmology
Biogen’s High Hopes For Gene Therapy, Ophthalmology
ratings:
Length:
18 minutes
Released:
Oct 21, 2015
Format:
Podcast episode
Description
In July, Biogen signed a potential $1 billion-plus deal with Applied Genetic Technologies Corp. The deal, which included an equity investment, centered around AGTC’s leading gene therapy programs developing treatments for rare ophthalmic conditions X -Linked Retinoschisis (XLRS) and X-linked Retinitis Pigmentosa (XLRP).In this podcast, Josh Mandel-Brehm, Director, Business Development and M&A at Bio-gen,discusses how Biogen and AGTC spoke for over a year before the deal came together. Calling the eye, “the window into the brain,” Mandel-Brehm says neurology-focused Biogen might be looking to find new partners in the future.
Released:
Oct 21, 2015
Format:
Podcast episode
Titles in the series (100)
Ophthalmology Is A “Leading Franchise” At InterWest by OIS Podcast | Ophthalmology's leading Podcast